CoChat
Sign Up
Cited by 93Cutaneous lymphoproliferative disorders researchLymphoma Diagnosis and TreatmentMultiple Myeloma Research and Treatments

Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome

Querfeld, Christiane, Rosen, Steven T., Guitart, Joan, Duvic, Madeleine, Kim, Youn H., Dusza, Stephen W., Kuzel, Timothy M.·2014·Blood
DOI 10.1182/blood-2013-09-525915
Open this paper in CoChat — free account

Abstract

Key Points: Lenalidomide is effective in refractory advanced cutaneous T-cell lymphoma, with an overall response rate of 28%. Patients demonstrate a transient flare reaction in skin, blood, and/or lymph nodes that may be associated with improvement in disease burden.

Integrity signals

Registry

Crossref · 10.1182/blood-2013-09-525915

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Del(5q) is the most common cytogenetic abnormality in MDS; patients with this genetic aberration often present with a consistent clinical phenotype, termed the 5q− syndrome, which is more common in women than in men and has a relatively indolent course characterized by hypoplastic anaemia.

    “Del(5q) is the most common cytogenetic abnormality in MDS; patients with this genetic aberration often present with a consistent clinical phenotype, termed the ‘5q− syndrome’, which is more common in women than in men and has a relatively indolent course characterized by hypoplastic anaemia95.”

    From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [95]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Querfeld, C., Rosen, S. T., Guitart, J., Duvic, M., Kim, Y. H., Dusza, S. W., & Kuzel, T. M.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Northwestern University (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Stanford University (US)
  • Department of Medicine, Division of Hematology/Oncology and
ORCID
Venue
Blood
Publisher
American Society of Hematology
Published
2014-02-20
Volume
123
Issue
8
Pages
1159-1166
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood-2013-09-525915
OpenAlex
W1990288154
Cited by
93
References
38
Citations by year
2026: 2 · 2025: 9 · 2024: 3 · 2023: 4 · 2022: 8 · 2021: 11 · 2020: 13 · 2019: 8 · 2018: 9 · 2017: 6 · 2016: 9 · 2015: 5 · 2014: 5 · 2012: 1
FWCI
7.43
Type
journal article
Language
en
Open access
closed
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Funders
Celgene
Topics
  • Health Sciences › Medicine › Dermatology › Cutaneous lymphoproliferative disorders research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Keywords
lenalidomide, mycosis fungoides, Sézary syndrome, cutaneous T-cell lymphoma, refractory disease, monotherapy, fatigue, CD25+ T cells, CD4/CD8 ratio, Foxp3, CD8+ T cells, adverse events
MeSH terms
Lenalidomide, Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Immunologic Factors, Male, Middle Aged, Mycosis Fungoides, Sezary Syndrome, Thalidomide, Treatment Outcome, Disease-Free Survival, Angiogenesis Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review